Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Rejection Acute Renal Clear all

Conditions: Renal Failure
Interventions: LCP-Tacro tablets, Prograf; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions: Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab); Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Acute Rejection of Renal Transplant, Graft Failure
Interventions: Donor-derived cell-free DNA; Diagnostic Test
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions: Renal Transplantation; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year to 20 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kidney Transplant Rejection
Interventions: TruGraf® Testing; Diagnostic Test
Lead sponsor: Transplant Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Transplant; Failure, Kidney
Interventions: Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids; Drug
Lead sponsor: Gaetano Ciancio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Antibody-Mediated Rejection (AMR)
Interventions: Cinryze®, Placebo; Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 29
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: End-stage Renal Failure, Kidney Graft Rejection
Interventions: Blood drawing for immune monitoring and questionnaires; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Kidney Transplantation
Interventions: AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: End Stage Renal Disease, Renal Transplant
Interventions: Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Tolera Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation
Interventions: Cyclosporine, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 37
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Kidney Failure, Chronic
Interventions: Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rejection of Kidney Allograft
Interventions: Observational group; Other
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: DGF, Kidney Transplant; Complications
Interventions: Highly suppressive Treg measurement; Diagnostic Test
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: San Bernardino, California • St Louis, Missouri

Conditions: Liver Transplantation
Interventions: mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Conditions: Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions: Belatacept, VIB4920, Thymoglobulin, Methylprednisolone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more

Conditions: Renal Failure
Interventions: LCP-Tacro, Prograf; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Kidney Transplantation
Interventions: Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus; Procedure · Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Graft Rejection
Interventions: Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Kidney Transplantation
Interventions: Rituximab for transplant rejection; Drug
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Kidney Transplant Immunosuppression
Interventions: adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Acute (Cellular) Renal Allograft Rejection
Interventions: rATG; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions: dd-cfDNA Blood Test; Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin

Search by objective public record fields.

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

TruGraf® Testing in High-Risk Kidney Transplant Recipients

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Reference Group Trial for The ONE Study

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Blood Biomarkers in Pediatric Kidney Transplant Recipients

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Randomized Trial for Mixed Acute Rejection

Rituximab for Pediatric Renal Transplant Rejection

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

Single Dose rATG for Renal Allograft Rejection

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA